Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Toviaz Fesoterodine fumarate Overactive bladder List in a similar manner Complete
Trajenta Linagliptin Diabetes mellitus, type 2 List with clinical criteria and/or conditions Complete
Tramacet Tramadol hydrochloride /acetaminophen Acute pain Do not list Complete
Translarna ataluren Cancelled
Treanda Bendamustine hydrochloride Chronic Lymphocytic Leukemia (relapsed/refractory) Do not reimburse Complete
Treanda Bendamustine hydrochloride Chronic Lymphocytic Leukemia (first-line) Reimburse with clinical criteria and/or conditions Complete
Treanda Bendamustine hydrochloride Non-Hodgkin Lymphoma and Mantle Cell Lymphoma Reimburse Complete
Treanda (in combination with rituximab) Bendamustine hydrochloride Chronic Lymphocytic Leukemia Withdrawn
Trecondyv treosulfan Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) Reimburse with clinical criteria and/or conditions Complete
Trecondyv treosulfan Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (pediatric) Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Trelegy Ellipta fluticasone furoate/umeclidinium bromide/vilanterol trifenatate Asthma, maintenance Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Trelegy Ellipta fluticasone furoate umeclidinium vilanterol Chronic obstructive pulmonary disease (COPD) Reimburse with clinical criteria and/or conditions Complete
Trelstar Triptorelin pamoate Cancer, prostate List in a similar manner to other drugs in class Complete
Tremfya guselkumab Psoriatic arthritis Reimburse with clinical criteria and/or conditions Complete
Tremfya guselkumab Ulcerative colitis Pending
Tremfya guselkumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Tresiba insulin degludec Diabetes mellitus, Type 1 & 2 Reimburse with clinical criteria and/or conditions Complete
Tridural Tramadol hydrochloride Pain Do not list Complete
Trikafta elexacaftor / tezacaftor / ivacaftor and ivacaftor Cystic fibrosis, F508del CFTR mutation Reimburse with clinical criteria and/or conditions Complete
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del CFTR mutation, 2 years and older Reimburse with clinical criteria and/or conditions Complete
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del CFTR mutation, 6 years and older Reimburse with clinical criteria and/or conditions Complete
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older Active
Trintellix Vortioxetine Depression, major depressive disorder Withdrawn
Trintellix vortioxetine hydrobromide Major depressive disorder (MDD), adults. Reimburse with clinical criteria and/or conditions Complete
Trisenox Arsenic Trioxide Acute Promyelocytic Leukemia Reimburse Complete